Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
Updated: Striving for 2023 launch, Pfizer touts topline PhIII win for another mass market vaccine
One of the vaccines that Pfizer has pegged for a 2023 launch has hit the mark in Phase III, setting up a filing by the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
